opioid dependence
Pain · 2005–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| buprenorphine; buprenorphine with naloxone; methadone Treatment of opioid dependence within a framework of medical, social and psychological treatment. | Mar 2023 | Recommended with restriction | no section in document |
| buprenorphine with naloxone Treatment of opioid dependence within a framework of medical, social and psychological treatment. | Mar 2020 | Not recommended | input received |
| buprenorphine Maintenance treatment of opioid dependence within a framework of medical, social, and psychological treatment. | Mar 2019 | Recommended with restriction | unclear |
| buprenorphine/naloxone Treatment of patients with opioid dependence within a framework of medical, social and psychological treatment. | Nov 2019 | Not recommended | none received |
| buprenorphine Treatment of opioid dependence in adults and adolescents aged 16 years and over, administered as a prolonged-release once weekly or once monthly subcutaneous… | Nov 2018 | Not recommended | input received |
| buprenorphine + naloxone Treatment of opiate dependence within a framework of medical, social and psychological treatment. | Nov 2014 | Recommended | none received |
| buprenorphine hydrochloride with naloxone hydrochloride Treatment of opiate dependence, within a framework of medical, social and psychological treatment. | Nov 2005 | Recommended with restriction | no section in document |
| buprenorphine hydrochloride with naloxone hydrochloride Treatment of opiate dependence within a framework of medical, social and psychological treatment. | Nov 2005 | Recommended with restriction | no section in document |
What the PBS pays
$1,414M in government benefit over 2024–25, across 19,546,209 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| buprenorphine, buprenorphine with naloxone, methadone | $254M |
| buprenorphine + naloxone | $244.4M |
| buprenorphine hydrochloride with naloxone hydrochloride | $244.4M |
| buprenorphine with naloxone | $244.4M |
| buprenorphine/naloxone | $244.4M |
| buprenorphine | $182.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.